XVIVO: Liver Assist granted FDA Breakthrough Device Designation (BDD) - Redeye

The Breakthrough Device Designation (BDD) is a timely stepping stone for XVIVO and the Liver Assist solution. This status signals that the process toward a US launch is more robust. We can expect further information on XVIVO’s yearly CMD tomorrow afternoon.

Länk till analysen i sin helhet: https://www.redeye.se/research/855927/xvivo-liver-assist-granted-fda-breakthrough-device-designation-bdd?utm_source=finwire&utm_medium=RSS